Aubert G, Peyle V, Dumont N, el Fassi M, Dorche G
Service de Bactériologie, CHRU Hôpital Bellevue, Saint-Etienne.
Ann Biol Clin (Paris). 1990;48(7):449-54.
In the course of an Escherichia coli cholecystitis, demonstrated by positive blood cultures, the authors observed a therapeutic failure with amoxicillin/clavulanate, probably related to the isolation in blood cultures, nine days after the beginning of the treatment, of a beta-lactam resistant E. coli strain (MICs of the amoxicillin combined with clavulanate was 64 mg/l and ceftazidim 16 mg/l). The strains which were recovered before and after treatment were shown to have the same biotype and the same electrophoretic profile for bacterial esterases. The second strain exhibited a high level production of the mediated chromosomal cephalosporinase. In the agar diffusion test, this mutant was more easily detected by ceftazidim than by other third generation cephalosporins. In the middle-stay unit where the patient was cured, cephalosporinase high producing mutants of E. coli were recovered in 0.6 p. cent of the strains versus 5, 1 p. cent for strains with cephalosporinase phenotype and 46.6 p. cent for strains with penicillinase phenotype. This report illustrates the importance of associating two synergistic antibiotics to prevent the emergence of beta-lactam resistant mutants in the course of severe E. coli infections.
在一例经血培养证实的大肠杆菌性胆囊炎病程中,作者观察到阿莫西林/克拉维酸治疗失败,这可能与治疗开始九天后血培养中分离出一株对β-内酰胺耐药的大肠杆菌菌株有关(阿莫西林与克拉维酸联合的 MIC 为 64mg/L,头孢他啶为 16mg/L)。治疗前后分离出的菌株显示具有相同的生物型和相同的细菌酯酶电泳图谱。第二株菌株表现出介导的染色体头孢菌素酶高水平产生。在琼脂扩散试验中,该突变体用头孢他啶比用其他第三代头孢菌素更容易检测到。在患者治愈的中间停留单元中,大肠杆菌产头孢菌素酶的高突变体在菌株中占 0.6%,产头孢菌素酶表型的菌株占 5.1%,产青霉素酶表型的菌株占 46.6%。本报告说明了联合使用两种协同抗生素以防止在严重大肠杆菌感染过程中出现β-内酰胺耐药突变体的重要性。